THE CONAFAY GROUP, LLC for MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 20, 2026 | $50,000 | Replaced |
| 3rd Quarter - Report | Oct 20, 2026 | $50,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Foreign entity interest: Maat Pharma; Freya Biosciences; Aimmune Therapeutics
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN L GARDNER | Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger |
| JOSH NARROW | Intern Senator Casey |
Medical/Disease Research/Clinical Labs MED
FY27 appropriations; education about the microbiome and federal research opportunities. FDA reforms.
Foreign entity interest: Maat Pharma;Freya Biosciences; Aimmune Therapeutics
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN L GARDNER | Legislative Correspondent Senator Tim Hutchinson; Research Assistant Senate HELP Committee; Chief of Staff Congresswoman Kay Granger |
| JOSH NARROW | Intern Senator Casey |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.